
What Pharma Is Buying From AI Drug Discovery: Inside AstraZeneca’s insitro Deal
Dr. Dereck Mush, MD, MBAInvestment firm
Perceptive was founded in 1999 and manages about $11 billion across its strategies as of June 30, 2026. Its funds include the Perceptive Life Sciences Fund, the Perceptive Credit Opportunities Fund, and the Perceptive Xontogeny Venture Fund, and chief executive Joseph Edelman says the firm examines biotechnologies for efficacy and impact. Its office is at Astor Place in New York. HTS covered Perceptive leading Talkiatry's $210 million Series D, with a16z participating. Talkiatry employs more than 800 psychiatrists and runs its scheduling and back office on its own AI software.
Perceptive Advisors invests in the life sciences industry through public equity, credit, capital solutions, and venture strategies.
How Perceptive Advisors got here, step by step.
1999
Perceptive Advisors is founded to invest in life sciences.
Venture fund
Venture fund
Venture fund
Venture fund
Health system venture investor
Corporate venture

Dr. Dereck Mush, MD, MBA
Dr. Dereck Mush, MD, MBAThe HealthTech Signal
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Dr. Dereck Mush, MD, MBA
Dr. Dereck Mush, MD, MBAKeep exploring
Your daily HealthTech Signal
Get the latest HealthTech news, understand why it matters, and see where the industry is headed.



Read by teams at companies like: